Effect of Empagliflozin on Intestinal Microbiota in Patients With Heart Failure (LVEF>40%）
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Empagliflozin was recommended for patients with heart failure with reduced ejection fraction
(HFrEF) in 2021 European Society of Cardiology (ESC) guidelines (Class of Recommendation Ia)
and patients with heart failure with preserved ejection fraction (HFpEF) in 2022 American
Heart Association (AHA) guidelines (Class of Recommendation IIa). However, the
physiopathologic mechanisms in its effects on HFpEF are not clear. Studies illustrate that
gut microbiota plays an essential role in the progress of the heart failure. Studies on mice
found that sodium-glucose cotransporter-2 inhibitors (sglt-2i) could affect the intestinal
microbiota in mice. The purpose of this study is to clarify the changes of gut microbiota in
the patients with non-reduced ejection fraction taking Empagliflozin and explore the role of
gut microbiota in this process.